Literature DB >> 1952844

Beta-lactamase of Mycobacterium fortuitum: kinetics of production and relationship with resistance to beta-lactam antibiotics.

L Fattorini1, G Scardaci, S H Jin, G Amicosante, N Franceschini, A Oratore, G Orefici.   

Abstract

The kinetics of both intracellular and extracellular beta-lactamase production and the relationship between extracellular enzyme and in vitro susceptibility of Mycobacterium fortuitum to beta-lactam antibiotics have been studied. To this end we used a panel of stable nitrosoguanidine-induced mutants of M. fortuitum derived from the parental strain ATCC 19542 and differing in beta-lactamase production from 0.0001 to 278 U/liter in Mueller-Hinton broth. For overproducers of beta-lactamase (mutants A188, B180, C207, D316, and E31), MICs of benzylpenicillin, amoxicillin, ampicillin, and cephaloridine progressively increased with the amount of enzyme released into the medium, whereas MICs of imipenem and cefoxitin did not. The resistance of the mutants to amoxicillin was reduced up to 32-fold by clavulanic acid, whereas that to ampicillin was reduced 8-fold by sulbactam. These data suggest that the enzyme participated in the mechanisms of resistance to the beta-lactam antibiotics. However, for a mutant of M. fortuitum (gamma 27) with virtually nonexistent beta-lactamase production, the antibiotics still had relatively high MICs (for instance, benzylpenicillin and cephaloridine had MICs of 64 and 32 micrograms/ml, respectively). This suggests that, aside from beta-lactamase production, other mechanisms such as cell wall permeability and/or affinity for penicillin-binding proteins could coexist in M. fortuitum and explain its natural resistance to beta-lactam antibiotics.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1952844      PMCID: PMC245264          DOI: 10.1128/AAC.35.9.1760

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Biochemical mechanisms of antibiotic resistance in a clinical isolate of Mycobacterium fortuitum. Presence of beta-lactamase and aminoglycoside-acetyltransferase and possible participation of altered drug transport on the resistance mechanism.

Authors:  T Udou; Y Mizuguchi; T Yamada
Journal:  Am Rev Respir Dis       Date:  1986-04

2.  Characterization of beta-lactamase from Mycobacterium butyricum ATCC 19979.

Authors:  D Choubey; K P Gopinathan
Journal:  Biochem Int       Date:  1986-02

3.  Inhibitors and inactivators of beta-lactamase from Mycobacterium fortuitum.

Authors:  L Fattorini; G Amicosante; D Fiorentino; N Franceschini; L Di Marzio; A Oratore; G Orefici
Journal:  J Chemother       Date:  1989-10       Impact factor: 1.714

4.  Characterization of a beta-lactamase produced in Mycobacterium fortuitum D316.

Authors:  G Amicosante; N Franceschini; B Segatore; A Oratore; L Fattorini; G Orefici; J Van Beeumen; J M Frere
Journal:  Biochem J       Date:  1990-11-01       Impact factor: 3.857

5.  Properties of beta-lactamases produced by three species of mycobacteria.

Authors:  J E Kasik; L Peacham
Journal:  Biochem J       Date:  1968-05       Impact factor: 3.857

6.  In vitro susceptibility of Mycobacterium fortuitum to amoxicillin or cephalothin in combination with clavulanic acid.

Authors:  M H Cynamon; G S Palmer
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

7.  Nonspecific induction of beta-lactamase in Enterobacter cloacae.

Authors:  W Cullmann; W Dick; A Dalhoff
Journal:  J Infect Dis       Date:  1983-10       Impact factor: 5.226

8.  Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities.

Authors:  R J Wallace; J M Swenson; V A Silcox; M G Bullen
Journal:  J Infect Dis       Date:  1985-09       Impact factor: 5.226

9.  In vitro susceptibility of Mycobacterium fortuitum to N-formimidoyl thienamycin and several cephamycins.

Authors:  M H Cynamon; G S Palmer
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

Review 10.  Spectrum of disease due to rapidly growing mycobacteria.

Authors:  R J Wallace; J M Swenson; V A Silcox; R C Good; J A Tschen; M S Stone
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug
View more
  6 in total

Review 1.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

2.  Imaging tuberculosis with endogenous beta-lactamase reporter enzyme fluorescence in live mice.

Authors:  Ying Kong; Hequan Yao; Hongjun Ren; Selvakumar Subbian; Suat L G Cirillo; James C Sacchettini; Jianghong Rao; Jeffrey D Cirillo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-21       Impact factor: 11.205

3.  Use of the chromosomal class A beta-lactamase of Mycobacterium fortuitum D316 to study potentially poor substrates and inhibitory beta-lactam compounds.

Authors:  M Galleni; N Franceschini; B Quinting; L Fattorini; G Orefici; A Oratore; J M Frère; G Amicosante
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

4.  Resistance to beta-lactams in Mycobacterium fortuitum.

Authors:  L Fattorini; G Orefici; S H Jin; G Scardaci; G Amicosante; N Franceschini; I Chopra
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

5.  Rapid Tuberculosis Diagnosis Using Reporter Enzyme Fluorescence.

Authors:  Preeti Sule; Ronak Tilvawala; Toriq Mustapha; Hany Hassounah; Aneesa Noormohamed; Suprateek Kundu; Edward A Graviss; Grant K Walkup; Ying Kong; Jeffrey D Cirillo
Journal:  J Clin Microbiol       Date:  2019-11-22       Impact factor: 5.948

6.  Stabilization of Tuberculosis Reporter Enzyme Fluorescence (REFtb) Diagnostic Reagents for Use at the Point of Care.

Authors:  Maxim Lebedev; Aaron B Benjamin; Kent J Koster; Kathryn E Broyles; Sathish Kumar; Joseph M Jilka; Jeffrey D Cirillo
Journal:  Diagnostics (Basel)       Date:  2022-07-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.